
Humane Genomics
Humane Genomics is a YC Summer 2021 (S21) company. Based in New York, NY, USA. Team of 5.
About Humane Genomics
Summary
Humane Genomics engineers oncolytic RNA viruses designed to seek out and destroy cancer cells while leaving healthy tissue intact. The platform uses a dual-selectivity mechanism, controlling both which cells the virus infects and where it replicates, achieving an on-target to off-target kill ratio exceeding 1,000. The lead program targets pediatric liver cancer, replacing cytotoxic treatments that lack tumor specificity, in collaboration with oncology specialists at Texas Children's Hospital.
From the Y Combinator listing
A platform to make artificial viruses as cancer therapeutics.
Humane Genomics has developed a platform to engineer cancer killing viruses. We have taken a first principles approach to design and make oncolytic viral therapies. Using a highly lytic RNA virus engineered with "2 factor authentication" (using selective infection and selective replication) they have an on-target to off-target kill ratio > 1000. We are working on our first indication, pediatric liver cancer (hepatoblastoma), with our partners at Texas Children's Hospital, who are world leading experts. We have in vivo (mouse) data showing safety and currently developing efficacy data and are showing 50% reduction in tumor volume.
Facts
- Healthcare / Healthcare -> Therapeutics
- New York, NY, USA
- 5
- Active
- Early
Founders (2)
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works